Cabaletta presents ‘promising’ results across indications, says H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao reiterates a Buy rating and $25 price target on shares of Cabaletta, telling investors in a research note that “promising” initial efficacy and safety data from myositis, lupus and scleroderma cohorts solidify Cabaletta’s position as a leader in developing cell therapy for autoimmune disease. Cabaletta reported “compelling” new data from 18 patients who were dosed with rese-cel across the REST-Myositis, -SLE and SSc studies at EULAR 2025, with seven out of eight patients from -Myositis achieving a clinical response off all immunomodulators, while off or actively tapering steroids and seven out of seven patients from -SLE achieved a clinical response off all immunomodulators and glucocorticoids, the firm says.